The latest price target for Portage Biotech (NASDAQ:PRTG) was reported by HC Wainwright & Co. on January 8, 2024. The analyst firm set a price target for $0.00 expecting PRTG to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Portage Biotech (NASDAQ:PRTG) was provided by HC Wainwright & Co., and Portage Biotech downgraded their neutral rating.

There is no last upgrade for Portage Biotech

The last downgrade for Portage Biotech Inc happened on January 8, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Portage Biotech Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Portage Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Portage Biotech was filed on January 8, 2024 so you should expect the next rating to be made available sometime around January 8, 2025.

While ratings are subjective and will change, the latest Portage Biotech (PRTG) rating was a downgraded with a price target of $0.00 to $0.00. The current price Portage Biotech (PRTG) is trading at is $10.16, which is out of the analyst’s predicted range.